DCN and pulmonary fibrosis: As seen from the above results, DCN-overexpressing MSCs demonstrated better therapeutic potential in pulmonary fibrosis, as reflected by the fact that a smaller dose achieved a therapeutic effect roughly comparable to that of high-dose MSC-Con.